TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22889884

Group type: EXPERIMENTAL
Intervention: Fast IOL insertion (1 revolution per second)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Slow IOL insertion (¼ revolution per second)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Group F)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 20093960

Group type: EXPERIMENTAL
Intervention: Free weight bench press at 70% 1RM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Free weight bench press at 90% 1RM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Smith machine bench press at 70% 1RM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Smith machine bench press at 90% 1RM
Number of subjects: 0
Study: 17106431

Group type: EXPERIMENTAL
Intervention: Gaze Stabilization Test (GST)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy subjects (control)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Patients with unilateral vestibular dysfunction
Number of subjects: 14
Study: 15111228

Group type: EXPERIMENTAL
Intervention: Stop signal task combined with flanker task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stop signal task combined with manual version of the Stroop task
Number of subjects: 0
Study: 11572296

Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomers
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Conventional resin-based composites
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Conventional glass-ionomers
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (10 additional teeth)
Number of subjects: 80
Study: 10321449

Group type: EXPERIMENTAL
Intervention: Moxonidine (antihypertensive doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxonidine (non-antihypertensive doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sympathicolytic agents
Number of subjects: 0
Study: 7933259

Group type: EXPERIMENTAL
Intervention: Repeat percutaneous transluminal angioplasty (rPTA)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Arterial bypass
Number of subjects: 93

Group type: COMPARATOR
Intervention: Noninvasive therapy (exercise and medication)
Number of subjects: 93
Study: 3202402

Group type: EXPERIMENTAL
Intervention: Methylprednisolone, 30 mg/kg per dose, 4 doses every 6 hours
Number of subjects: 87

Group type: COMPARATOR
Intervention: Mannitol placebo
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 87
Study: 30132011

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise with a behavioural approach
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise
Number of subjects: 165

Group type: COMPARATOR
Intervention: Prescribed physical activity intervention
Number of subjects: 165
Study: 27362929

Group type: EXPERIMENTAL
Intervention: Femoral nerve block (FNB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 24347440

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 50
Study: 24107896

Group type: EXPERIMENTAL
Intervention: Early rehabilitation for stroke patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy people (control group)
Number of subjects: 60
Study: 20339958

Group type: EXPERIMENTAL
Intervention: 8‐NitroG and 8‐OHdG expression in NPC patients
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Serum 8‐OHdG levels in NPC patients
Number of subjects: 59
Study: 19034247

Group type: EXPERIMENTAL
Intervention: Forced-air warming device (BairHugger 505 and Upper Body Blanket 522)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Resistive heating device (Geratherm Adult system)
Number of subjects: 6
Study: 17165297

Group type: EXPERIMENTAL
Intervention: 2-step bonding system (Excite DSC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: 3-step adhesive (Syntac)
Number of subjects: 39
Study: 14581709

Group type: EXPERIMENTAL
Intervention: Soft silicone dressing
Number of subjects: 38

Group type: COMPARATOR
Intervention: Hydropolymer dressing
Number of subjects: 38
Study: 10690822

Group type: EXPERIMENTAL
Intervention: Topical 0.01% mitomycin-C eye drops (n = 17)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 26
Study: 9302957

Group type: EXPERIMENTAL
Intervention: Community based coronary heart disease health promotion project
Number of subjects: 0
Study: 8243490

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 200 mg every 12 h for 7 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Amoxicillin 500 mg every 8 h for 7 days
Number of subjects: 10
Study: 3905411

Group type: EXPERIMENTAL
Intervention: amitriptylinoxide
Number of subjects: 57

Group type: COMPARATOR
Intervention: trazodone
Number of subjects: 57
Study: 31108180

Group type: EXPERIMENTAL
Intervention: FeNO treatment algorithm
Number of subjects: 88

Group type: COMPARATOR
Intervention: Guideline-based management
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: FeNO alone
Number of subjects: 88
Study: 26393814

Group type: EXPERIMENTAL
Intervention: Plyometric Training (PT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Aquatic Plyometric Training (APT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 65
Study: 26586093

Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy with capecitabine and thalidomide after RFA
Number of subjects: 50

Group type: COMPARATOR
Intervention: RFA only
Number of subjects: 50
Study: 27036656

Group type: EXPERIMENTAL
Intervention: Tat Oyi vaccine (33 µg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tat Oyi vaccine (11 µg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tat Oyi vaccine (99 µg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (0 µg Tat Oyi)
Number of subjects: 48
Study: 22458392

Group type: EXPERIMENTAL
Intervention: Zinc sulfate (440 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 19521723

Group type: EXPERIMENTAL
Intervention: Initial chemotherapy for breast cancer
Number of subjects: 0
Study: 18315512

Group type: EXPERIMENTAL
Intervention: Baduanjin exercise (30-minute classes, five times a week for 8 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 28
Study: 16011670

Group type: EXPERIMENTAL
Intervention: H1 receptor antagonists (H1RA)
Number of subjects: 2366

Group type: EXPERIMENTAL
Intervention: H2 receptor antagonists (H2RA)
Number of subjects: 2366
Study: 12094340

Group type: EXPERIMENTAL
Intervention: Gemcitabine/carboplatin
Number of subjects: 332

Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 332
Study: 10367259

Group type: EXPERIMENTAL
Intervention: 740 mg/m2 amifostine administered before chemotherapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no amifostine)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups received 2.6 g/m2 5-fluorouracil and 500 mg/m2 folinic acid per week for 6 weeks
Number of subjects: 27
Study: 7586593

Group type: EXPERIMENTAL
Intervention: 10 mg of methimazole per day
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: 40 mg of methimazole per day
Number of subjects: 509
Study: 1934382

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg over 30 minutes followed by 1 mg.kg‐1.hr‐1 for 12 hours)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Desmopressin (0.3 micrograms/kg over 20 minutes after protamine infusion)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Combination of tranexamic acid and desmopressin
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 6502335

Group type: EXPERIMENTAL
Intervention: Iron treatment
Number of subjects: 467

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 467
Study: 30876451

Group type: EXPERIMENTAL
Intervention: Stunting (chronic undernutrition)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Nutrition interventions targeting rural areas
Number of subjects: 378
Study: 30592459

Group type: EXPERIMENTAL
Intervention: Whole cell pneumococcal vaccine (WCV)
Number of subjects: 35
Study: 25727449

Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction
Number of subjects: 15

Group type: COMPARATOR
Intervention: One-on-one tutoring
Number of subjects: 15
Study: 24534139

Group type: EXPERIMENTAL
Intervention: Enhanced Internet treatment
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Self-efficacy and website logins
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Latency to TQD
Number of subjects: 825
Study: 22367657

Group type: EXPERIMENTAL
Intervention: Levetiracetam (500-2000 g/d)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 20733097

Group type: EXPERIMENTAL
Intervention: CRT plus ICD
Number of subjects: 1820

Group type: COMPARATOR
Intervention: ICD only
Number of subjects: 1820
Study: 17685090

Group type: EXPERIMENTAL
Intervention: Astaxanthin supplementation (2 capsules of 4 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (2 identical-looking capsules)
Number of subjects: 0
Study: 17348558

Group type: EXPERIMENTAL
Intervention: Pre-adjusted edgewise appliance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 15246795

Group type: EXPERIMENTAL
Intervention: New extrication technique
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard extrication technique
Number of subjects: 12
Study: 10626717

Group type: EXPERIMENTAL
Intervention: Isobaric 9.75 mg bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hyperbaric 9.75 mg bupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural injections of 3 ml lidocaine 2%
Number of subjects: 60
Study: 9369106

Group type: EXPERIMENTAL
Intervention: Local glyceryl trinitrate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sphincterotomy
Number of subjects: 24
Study: 1384150

Group type: EXPERIMENTAL
Intervention: Functioning activation rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spa resort rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cluster analysis technique for psychological profiles
Number of subjects: 0
Study: 3985903

Group type: EXPERIMENTAL
Intervention: Analgesics
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Slow cooling
Number of subjects: 8
Study: 31870938

Group type: EXPERIMENTAL
Intervention: Isomaltulose
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 35
Study: 30604407

Group type: EXPERIMENTAL
Intervention: Fine Needle Aspiration Biopsy (FNAB)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tru-Cut Core Biopsy
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Biopsy complications
Number of subjects: 19
Study: 28456902

Group type: EXPERIMENTAL
Intervention: Cathodal ctDCS
Number of subjects: 15
Study: 25966452

Group type: EXPERIMENTAL
Intervention: Access to subsidized bed nets
Number of subjects: 516

Group type: COMPARATOR
Intervention: Control group (no access to subsidized bed nets)
Number of subjects: 516
Study: 23444228

Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg plus gp100 vaccine
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg plus placebo
Number of subjects: 676

Group type: COMPARATOR
Intervention: gp100 vaccine alone
Number of subjects: 676
Study: 21527171

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (energy and protein enriched diet, oral nutritional support, calcium‐vitamin D supplement, telephone counseling by a dietitian) for 3 months postdischarge
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 210
Study: 18316115

Group type: EXPERIMENTAL
Intervention: Home-based brisk walking program (12 weeks, expending at least 300 kcal each walk)
Number of subjects: 67
Study: 17001943

Group type: EXPERIMENTAL
Intervention: Leg Club model (n=28)
Number of subjects: 56
Study: 14527570

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 0
Study: 11885181

Group type: EXPERIMENTAL
Intervention: HA-coated implants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-coated implants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All implants in bone qualities 1 and 2 (BQ-1 and BQ-2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All implants in bone qualities 3 and 4 (BQ-3 and BQ-4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PTVs at uncovering
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PTVs fluctuation during routine healing and loading
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Critical PTV
Number of subjects: 0
Study: 8797220

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 1396838

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy with warfarin (n = 102)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Dipyridamole and aspirin (n = 130)
Number of subjects: 232
Study: 4040486

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 5
Study: 30624278

Group type: EXPERIMENTAL
Intervention: Continuous electroencephalography
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Continuous electroencephalography background features
Number of subjects: 152
Study: 29275333

Group type: EXPERIMENTAL
Intervention: Adalimumab (24 mg/m2 for patients <13 years, 40 mg for others) administered subcutaneously every other week.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 28008239

Group type: EXPERIMENTAL
Intervention: Resistance training group performing two sessions/week (RT2, n=8)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Resistance training group performing three sessions/week (RT3, n=8)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CG, n=8)
Number of subjects: 24
Study: 23993735

Group type: COMPARATOR
Intervention: Sufentanil 0.2 ng/ml
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.4 ng/ml
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.5 ng/ml
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sufentanil for wound management
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sufentanil for uncovering inner layer dressings
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 80
Study: 22607233

Group type: EXPERIMENTAL
Intervention: Gatifloxacin-containing 4-month regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 20883738

Group type: COMPARATOR
Intervention: DTaP 0.2 ml
Number of subjects: 551

Group type: COMPARATOR
Intervention: DTaP 0.5 ml
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: DTaP 0.2 ml and DTaP 0.5 ml
Number of subjects: 551
Study: 17653013

Group type: EXPERIMENTAL
Intervention: Amiodarone treatment (900 mg/day intravenously for the first 2 days, then 600 mg/day)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Nontreated group
Number of subjects: 111
Study: 14698516

Group type: EXPERIMENTAL
Intervention: Neem (Azadirachta indica) leaf extract dental gel (25 mg/g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorhexidine gluconate mouthwash (0.2% w/v)
Number of subjects: 0
Study: 11696124

Group type: EXPERIMENTAL
Intervention: Dexamethasone plus low-dose ondansetron (50 microg.kg(‐1) ondansetron i.v.)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Dexamethasone alone (placebo)
Number of subjects: 193
Study: 9263718

Group type: EXPERIMENTAL
Intervention: Non-invasive diagnosis and conservative treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Further large-scale studies
Number of subjects: 0
Study: 8427724

Group type: EXPERIMENTAL
Intervention: Ondansetron (16 mg) orally three times daily starting 24 hours after cisplatin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo orally three times daily starting 24 hours after cisplatin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ondansetron (16 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 3319537

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OCBZ)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 48
Study: 30097902

Group type: EXPERIMENTAL
Intervention: Conversation maps‐based (CM™) education
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Individual education (IE)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 90
Study: 29351295

Group type: EXPERIMENTAL
Intervention: Embrace
Number of subjects: 1456

Group type: COMPARATOR
Intervention: CAU
Number of subjects: 1456
Study: 27743903

Group type: EXPERIMENTAL
Intervention: rexlemestrocel-L 150×10^6
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rexlemestrocel-L 300×10^6
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 24815499

Group type: EXPERIMENTAL
Intervention: Fluid Watchers LITE
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Fluid Watchers PLUS
Number of subjects: 602

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 602
Study: 21996146

Group type: EXPERIMENTAL
Intervention: Prasugrel therapy (loading dose 60 mg; maintenance dose 5 mg/day for patients ≥75 years old or ≤60 kg; 10 mg/day for others)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Prasugrel therapy
Number of subjects: 298
Study: 20810472

Group type: EXPERIMENTAL
Intervention: Parent-focused intervention
Number of subjects: 146

Group type: COMPARATOR
Intervention: Monitoring-only condition
Number of subjects: 146
Study: 17936422

Group type: EXPERIMENTAL
Intervention: Open surgical technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgical technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 0
Study: 16294652

Group type: EXPERIMENTAL
Intervention: Screening for depressive symptoms using the PHQ-9
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Active management with medication or referral to a mental health specialist
Number of subjects: 51
Study: 12450703

Group type: EXPERIMENTAL
Intervention: MMRV vaccine
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: MMR/V vaccine
Number of subjects: 240

Group type: COMPARATOR
Intervention: MMR vaccine
Number of subjects: 240
Study: 10475656

Group type: EXPERIMENTAL
Intervention: Glove perforation indication system
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard surgical glove
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Hand-held mandibular fractures
Number of subjects: 113

Group type: COMPARATOR
Intervention: Temporary intermaxillary fixation
Number of subjects: 113
Study: 8734231

Group type: EXPERIMENTAL
Intervention: 0.375% bupivacaine, 0.6 mL.kg‐1 intraperitoneally
Number of subjects: 24

Group type: COMPARATOR
Intervention: NaCl 0.9%
Number of subjects: 24
Study: 1721980

Group type: EXPERIMENTAL
Intervention: Carvedilol (25-50 mg once daily)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) (25-50 mg once daily)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 201

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 201
Study: 31126570

Group type: EXPERIMENTAL
Intervention: Vaccinium arctostaphylos berry extract (400 mg capsule, three times daily for 3 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 27755056

Group type: EXPERIMENTAL
Intervention: Laryngoscope-assisted lightwand technique (group L, n = 82)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Conventional lightwand technique (group C, n = 80)
Number of subjects: 162
Study: 26018581

Group type: EXPERIMENTAL
Intervention: Outpatient double-balloon catheter cervical ripening (n = 33)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Inpatient double-balloon catheter cervical ripening (n = 15)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (outpatient and inpatient)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Midwives and doctors (n = 90)
Number of subjects: 48
Study: 24467565

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) 0.4 U/kg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 37
Study: 22479361

Group type: EXPERIMENTAL
Intervention: High-dose vitamin A (200,000 IU) in addition to daily low-dose vitamin A (5000 IU) for 15 days.
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo in addition to daily low-dose vitamin A (5000 IU) for 15 days.
Number of subjects: 260
Study: 19017676

Group type: EXPERIMENTAL
Intervention: Higher dose exercise programme (60 min/day) conducted whilst standing
Number of subjects: 160

Group type: COMPARATOR
Intervention: Lower dose exercise programme (30 min/day) primarily conducted whilst seated/supine
Number of subjects: 160
Study: 17515696

Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl (90 mg) following a high-fat, high-caloric meal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl (90 mg) following a low-fat, low-caloric meal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cinacalcet HCl (90 mg) under fasting conditions
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl (90 mg) following high-fat meal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl (90 mg) following low-fat meal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl (90 mg) across all treatment conditions
Number of subjects: 30
Study: 15126996

Group type: EXPERIMENTAL
Intervention: Exercise training for 8 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Matched control subjects
Number of subjects: 14
Study: 10869738

Group type: EXPERIMENTAL
Intervention: Boost of 16 Gy to the primary tumor bed
Number of subjects: 5569

Group type: COMPARATOR
Intervention: No further treatment (no boost)
Number of subjects: 5569

Group type: EXPERIMENTAL
Intervention: Panel evaluation
Number of subjects: 5569

Group type: EXPERIMENTAL
Intervention: Digitizer measurements
Number of subjects: 5569
Study: 9184703

Group type: EXPERIMENTAL
Intervention: Glimepiride 3 mg twice daily
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Glimepiride 6 mg once daily
Number of subjects: 161

Group type: COMPARATOR
Intervention: Glimepiride (both regimens)
Number of subjects: 161